UNSPSC 51433003: Rilmenidine dihydrogen phosphate

This classification denotes an antihypertensive agent with the molecular formula C10H16N2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59QD64Q32M, chemically known as 4,5-dihydro-n-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1) but more generally known as rilmenidine dihydrogen phosphate, which bears US NIH Compound Identifier 198614. European Medicines Agency schedules Rilmenidine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21586.

Most nations, for tariff and trade purposes, schedule rilmenidine dihydrogen phosphate under HS 29349990. SMILES: C1CC1C(C2CC2)NC3=NCCO3.OP(=O)(O)O.

UNSPSC 51433003 Rilmenidine dihydrogen phosphate is a Commodity code with minimal recent state and local procurement activity. The single recent opportunity on record—a City of Tampa Fire Rescue medication procurement—does not involve rilmenidine; it solicits epinephrine, labetalol, adenosine, and diltiazem for Advanced Life Support protocols. The mismatch between the code's nominal scope (a specific antihypertensive pharmaceutical) and the actual goods being bought under it suggests this code sees little relevant activity in state and local contracting today.

The City of Tampa Purchasing Department issued ITB 26P00188 on April 24, 2026, with a response deadline of April 8, 2026 (note: the due date predates the posting date in the source data), seeking four medication line items totaling approximately 3,550 units with an estimated contract value of $40,000.00. The contract carries a one-year initial term with two optional one-year renewals and unilateral extension rights for up to three additional 30-day periods. The solicitation includes a Small Local Business Enterprise sheltered market designation offering a five percent bid discount capped at $10,000, and requires vendors to meet WCAG 2.2 Level AA accessibility standards and OSHA Hazard Communication Standards. Delivery must occur within ten calendar days of order, and all medications must maintain a minimum nine-month expiration date at acceptance. This appears to be the only recent state and local opportunity tagged to this code; activity remains insufficient to characterize an issuing-body mix or broader geographic concentration.